Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171834 · ClinicalTrials.gov registry record · Phase 1
Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
NCT00171834 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 89 participants.
The verdict
NCT00171834, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
Study Summary
The study objective is to evaluate the maximum tolerated dose, safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy.
Interventions
- DRUG Patupilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2003-08 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171834
The ClinicalTrials.gov registry entry for NCT00171834 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patupilone is the first listed.
NCT00171834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00171834 about?
NCT00171834 is a clinical study titled "Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer". The study objective is to evaluate the maximum tolerated dose, safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy.
What is the current status of trial NCT00171834?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2003-08. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00171834?
The interventions under investigation include: Patupilone (DRUG).
Who is sponsoring clinical trial NCT00171834?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.